Study #2022-0303
A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
NTX-1088, Pembrolizumab
Description
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.